• Register Now
  • HOME
  • AGENDA
  • VENUE
  • CONTACT
  • Register Now

AGENDA

  • Friday, September 26th 2025
  • Saturday, September 27th 2025
13.00 - 14.00
Lunch
14.00 - 14.15
Opening and welcome
14.15 - 15.35
SESSION 1: PNH overview
14.15 - 14.30
Natural history of PNH & Patophysiology
14.30 - 14.45
The fundamentals of IVH, EVH & BTH, including pharmacokinetic & pharmacodynamic BTH
14.45 - 15.00
Thrombosis management in PNH
15.00 - 15.15
PNH & aplastic anaemia: an unmet need
15.15 - 15.35
Roundtable discussion
15.35 - 15.50
Coffee break
15.50 - 17.10
SESSION 2: C5 inhibition
15.50 - 16.05
C5 inhibition history, clinical trials on eculizumab and ravulizumab & real world evidence
16.05 - 16.15
Case report: Challenging patient treated with ravulizumab
16.15 - 16.20
Discussion
16.20 - 16.35
Battling with PNH from physician’s perspective
16.35 - 16.40
Discussion
16.40 - 16.55
Crovalimab clinical trials data
16.55 - 17.05
Case report: Challenging patient treated with crovalimab
17.05 - 17.10
Discussion
17.10 - 17.30
Coffee break
17.30 - 18.40
SESSION 3: PNH worldwide & varia
17.30 - 17.40
PNH in US & Canada
17.40 - 17.50
PNH in Western Europe
17.50 - 18.00
PNH in Central-Eastern Europe
18.00 - 18.10
Is there a place for alloHSCT in PNH?
18.10 - 18.35
PNH in Ukraine & discussion
18.35 - 18.40
Day 1 wrap-up
19.30
Dinner
9.00 - 10.25
SESSION 4: Proximal complement inhibition
9.00 - 9.15
C3 inhibition: clinical trials and RWE on pegcetacoplan
9.15 - 9.30
Factor B inhibitor Iptacopan: clinical trials evidence
9.30 - 9.45
Factor D inhibitor Danicopan: clinical trials evidence
9.45 - 10.00
Novel proximal inhibitors: MASP3 inhibitor clinical trial evidence
10.00 - 10.25
Roundtable discussion
10.25 - 10.40
Coffee break
10.40 - 11.40
SESSION 5: Patient cases on proximal inhibitors
10.40 - 10.55
Case report: Patient with EVH on C5 inhibitor treated with pegcetacoplan
10.55 - 11.00
Discussion
11.00 - 11.15
Case report: Patient treated with danicopan as an add-on to ravulizumab
11.15 - 11.20
Discussion
11.20 - 11.35
Case report: Patient treated with iptacopan monotherapy
11.35 - 11.40
Discussion
11.40 - 12.00
Coffee break
12.00 - 12.30
Polish point of view: What therapeutic options do we have and what would we like to have? Roundtable discussion
12.30 - 13.35
SESSION 6: Registries & Mission
12.30 - 12.45
IPIG history and mission
12.45 - 13.00
PNH Global Alliance mission
13.00 - 13.15
IPIG registry
13.15 - 13.40
What do you want to know about PNH: Q&A session + discussion
13.40 - 13.50
Summary and conclusions
13.50 - 14.50
Lunch


 
Participation in the conference is free of charge. The organiser will cover the fees and accommodation costs for participants.

Sponsors`s exhibition is intended for persons authorized to prescribe drugs or pharmacists and for persons trading in medial products – legal basis. Act of 6 September 2001. Pharmaceutical Law (Journal of Laws from 2021, item 1977).